全文获取类型
收费全文 | 4956篇 |
免费 | 473篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 46篇 |
儿科学 | 100篇 |
妇产科学 | 126篇 |
基础医学 | 742篇 |
口腔科学 | 233篇 |
临床医学 | 612篇 |
内科学 | 952篇 |
皮肤病学 | 43篇 |
神经病学 | 367篇 |
特种医学 | 183篇 |
外科学 | 600篇 |
综合类 | 104篇 |
一般理论 | 7篇 |
预防医学 | 544篇 |
眼科学 | 36篇 |
药学 | 423篇 |
中国医学 | 8篇 |
肿瘤学 | 309篇 |
出版年
2021年 | 59篇 |
2020年 | 55篇 |
2019年 | 74篇 |
2018年 | 87篇 |
2017年 | 74篇 |
2016年 | 74篇 |
2015年 | 84篇 |
2014年 | 105篇 |
2013年 | 145篇 |
2012年 | 246篇 |
2011年 | 256篇 |
2010年 | 122篇 |
2009年 | 117篇 |
2008年 | 218篇 |
2007年 | 216篇 |
2006年 | 252篇 |
2005年 | 214篇 |
2004年 | 209篇 |
2003年 | 171篇 |
2002年 | 179篇 |
2001年 | 175篇 |
2000年 | 189篇 |
1999年 | 123篇 |
1998年 | 65篇 |
1997年 | 54篇 |
1996年 | 43篇 |
1995年 | 60篇 |
1994年 | 56篇 |
1993年 | 50篇 |
1992年 | 107篇 |
1991年 | 124篇 |
1990年 | 104篇 |
1989年 | 84篇 |
1988年 | 57篇 |
1987年 | 85篇 |
1986年 | 95篇 |
1985年 | 82篇 |
1984年 | 65篇 |
1983年 | 62篇 |
1982年 | 39篇 |
1981年 | 33篇 |
1979年 | 62篇 |
1978年 | 45篇 |
1977年 | 42篇 |
1976年 | 33篇 |
1975年 | 41篇 |
1974年 | 48篇 |
1973年 | 34篇 |
1972年 | 45篇 |
1969年 | 41篇 |
排序方式: 共有5435条查询结果,搜索用时 15 毫秒
1.
Stephen D. Patterson Rachael Swan William Page Moacir Marocolo Owen Jeffries Mark Waldron 《Journal of Science and Medicine in Sport》2021,24(7):709-714
ObjectivesThe aim of this investigation was to determine if acute or repeated applications of ischemic preconditioning (IPC) could enhance the recovery process, following exercise induced muscle damage (EIMD).DesignRandomized control trial.MethodsTwenty-three healthy males were familiarised with the muscle damaging protocol (five sets of 20 drop jumps from a 0.6 m box) and randomly allocated to one of three groups: SHAM (3 × 5 min at 20 mmHg), Acute IPC (3 × 5 min at 220 mmHg) and Repeated IPC (3 days x 3 × 5 min at 220 mmHg). The indices of muscle damage measured included creatine kinase concentration ([CK]), thigh swelling, delayed onset muscle soreness, counter movement jumps (CMJ) and maximal voluntary isometric contraction (MVIC).ResultsBoth acute and repeated IPC improved recovery in MVIC versus SHAM. Repeated IPC led to a faster MVIC recovery at 48 h (101.5%) relative to acute IPC (92.6%) and SHAM (84.4%) (P < 0.05). Less swelling was found for both acute and repeated IPC vs. SHAM (P < 0.05) but no group effects were found for CMJ, soreness or [CK] responses (P > 0.05).ConclusionTaken together, repeated IPC can enhance recovery time of MVIC more than an acute application, and both reduce swelling following EIMD, relative to a SHAM condition. 相似文献
2.
Hailu Tilahun Sarah J. Masyuko Jerusha N. Mogaka Tecla Temu John Kinuthia Alfred O. Osoti Damalie Nakanjako Carey Farquhar Stephanie T. Page 《Medicine》2021,100(10)
There is increasing morbidity and mortality from cardiovascular diseases (CVD) in sub-Saharan Africa (SSA). Dyslipidemia is a well-known CVD risk factor which has been associated with human immunodeficiency virus (HIV) infection and its treatment in high-income countries. Studies in SSA that have examined the relationship between HIV and dyslipidemia have reported mixed results. In this study, we sought to determine the prevalence of dyslipidemia in HIV positive and negative adults (>=30 years old) and evaluate for association in Western Kenya with a higher prevalence expected among HIV positive individuals.HIV positive adults receiving antiretroviral therapy (ART) and HIV negative individuals seeking HIV testing and counseling services were recruited into a cross-sectional study. Demographic and behavioral data and fasting blood samples were collected. Dyslipidemia was defined according to the National Cholesterol Education Program Adult Treatment Panel III. Associations between baseline demographic and clinical variables and dyslipidemia were analyzed using logistic regression.A total of 598 participants, 300 HIV positive and 298 HIV negative adults were enrolled. Dyslipidemia data was available for 564 (94%) participants. In total, 267 (47%) had dyslipidemia. This was not significantly different between HIV positive and HIV negative individuals (46% vs 49%, P = .4). In a multivariate analysis including both HIV positive and negative individuals, adults 50 to 59 years of age had a 2-fold increased risk of dyslipidemia (Odds ratio [OR] 2.1, 95% confidence interval (1.2–3.5) when compared to 30 to 39-years-old participants. Abdominal obesity (OR 2.5), being overweight (OR 1.9), and low fruit and vegetable intake (OR 2.2) were significantly associated with dyslipidemia. Among HIV positive participants, time since HIV diagnosis, ART duration, use of (PI) protease inhibitor-based ART, viral load suppression, current cluster of differentiation (CD4) count and nadir CD4 did not have significant associations with dyslipidemia.The prevalence of dyslipidemia is high in Western Kenya, with nearly half of all participants with lipid abnormalities. Dyslipidemia was not significantly associated with HIV status, or with HIV-specific factors. Older age, being overweight, abdominal obesity, and low fruit and vegetable intake were associated with dyslipidemia and may be targets for public health interventions to lower the prevalence of dyslipidemia and CVD risk in sub-Saharan Africa. 相似文献
3.
4.
5.
6.
7.
David Page 《Haemophilia》2020,26(Z3):4-5
The history of the development of comprehensive care for hemophilia and other inherited bleeding disorders in Canada has been long and full of challenges. From limited in‐patient treatment with plasma and cryoprecipitate in a few major centres in the 1950s and 1960s, a network of Hemophilia Treatment Centres (HTCs) offering multi‐disciplinary comprehensive care, home infusion and prophylaxis was established across the country by the late 1970s and early 1980s, only to be shaken by the widespread contamination of factor concentrates with HIV and HCV in the 1970s and 1980s. In recent years the mission of HTCs has expanded to better serve people with von Willebrand disease, rare factor deficiencies and other rare bleeding disorders, and more fully recognize the needs of women with bleeding disorders. In 2020, challenges remain, notably maintaining the resources and expertise in HTCs and gaining access to the latest innovations in treatments. 相似文献
8.
9.
David R. Spigel Robert M. Jotte Santiago Ponce Aix Laurent Gressot Daniel Morgensztern Michael McCleod Mark A. Socinski Davey Daniel Oscar Juan-Vidal Kathryn F. Mileham Howard West Ray Page Niels Reinmuth Jeanna Knoble Tianlei Chen Rafia Bhore Marianne Wolfsteiner Teng Jin Ong Michael Thomas 《Clinical lung cancer》2021,22(1):6-15.e4
BackgroundWe evaluated maintenance nanoparticle albumin-bound (nab) paclitaxel in the treatment of advanced squamous non–small-cell lung cancer.Patients and MethodsPatients with treatment-naive squamous non–small-cell lung cancer received four 21-day cycles of nab-paclitaxel 100 mg/m2 on days 1, 8, 15 plus carboplatin area under the curve 6 on day 1 as induction therapy. Patients without disease progression after induction were randomized 2:1 to maintenance nab-paclitaxel 100 mg/m2 (days 1 and 8 every 21 days) plus best supportive care (BSC) or BSC alone. The primary endpoint was progression-free survival (PFS). Secondary endpoints included safety and overall survival (OS).ResultsOverall, 420 patients had received induction therapy; 202 (nab-paclitaxel plus BSC, 136; BSC, 66) had received maintenance therapy. Enrollment was discontinued after a preplanned interim futility analysis (patients could remain in the study at the investigator’s discretion). The median PFS was 3.12 months for nab-paclitaxel plus BSC and 2.60 months for BSC; the difference was not statistically significant (hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.61-1.19; P = .36). The median OS (median follow-up, 24.2 months) was 17.18 months for nab-paclitaxel plus BSC and 12.16 months for BSC (HR, 0.70; 95% CI, 0.48-1.02; nominal P = .07). An updated analysis (median follow-up, 28.4 months) revealed a median OS of 17.61 months for nab-paclitaxel plus BSC and 12.16 months for BSC (HR, 0.68; 95% CI, 0.47-0.98; nominal P = .037). The most frequent grade 3 and 4 treatment-emergent adverse events for the entire study were neutropenia (53.1% [nab-paclitaxel plus BSC] vs. 50.0% [BSC]) and anemia (33.1% [nab-paclitaxel plus BSC] vs. 32.3% [BSC]). Only peripheral neuropathy had occurred in ≥ 5% of patients during maintenance therapy (13.1%; nab-paclitaxel plus BSC).ConclusionsThe results of the ABOUND.sqm did not meet the primary endpoint of PFS. An updated OS analysis revealed a trend favoring nab-paclitaxel plus BSC. 相似文献
10.
Jay R. Dave Ankush M. Dewle Suhas T. Mhaske Prashant T. Phulpagar Vikas L. Mathe Supriya E. More Ayesha A. Khan Appala Venkata Ramana Murthy Suwarna S. Datar Ajay J. Jog Megha Page Geetanjali B. Tomar 《Nanomedicine : nanotechnology, biology, and medicine》2019,15(1):218-230
Parathyroid hormone (PTH) has been a major contributor to the anabolic therapy for osteoporosis, but its delivery to bone without losing activity and avoiding adverse local effects remain a challenge. Being the natural component of bone, use of hydroxyapatite for this purpose brings a major breakthrough in synergistic anabolism. This study focuses on synthesis, characterization and evaluation of in vitro and in vivo efficacy of PTH (1-34) adsorbed hydroxyapatite nanocarrier for synergistic enhancement in the anabolic activity of PTH for bone regeneration. The negative zeta potential of this nanocarrier facilitated its affinity to the Ca2+ rich bone tissue and solubilization at low pH enhanced specific delivery of PTH to the resorption pits in osteoporotic bone. In this process, PTH retained its anabolic effect and at the same time an increase in bone mineral content indicated enhancement of the net formative effect of the PTH anabolic therapy. 相似文献